Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas (073)

F

French Innovative Leukemia Organisation

Status and phase

Completed
Phase 2

Conditions

Lymphoma

Treatments

Procedure: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)
Drug: CEEP regimen

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00869284
GOELAMS 073
no other identification number

Details and patient eligibility

About

Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.

Full description

High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years

Enrollment

45 patients

Sex

All

Ages

15 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients aged from 15 to 60 years
  • previously untreated
  • histologically proven aggressive NHL
  • high aa-IPI (equal to 3)
  • proper underlying organ function

Exclusion criteria

  • transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems